Adaptive Biotechnologies reported second quarter 2026 revenue of $71.6 million, a 22% increase year-over-year, driven by a 33% growth in its Minimal Residual Disease (MRD) segment to $66.2 million. The company completed a $345 million zero-coupon convertible senior notes offering and repaid the OrbiMed Purchase Agreement, resulting in a loss on extinguishment of $23.7 million. Consequently, net loss widened to $39.9 million from $25.6 million in the prior year period, though adjusted EBITDA improved to a loss of $0.7 million. Management raised full-year 2026 MRD revenue guidance to $268–$278 million and announced plans to separate its Immune Medicine business. Additionally, Co-founder and Chief Scientific Officer Dr. Harlan Robins transitioned to a strategic consultant role effective July 24, 2026. Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system to develop clinical diagnostics and therapies for cancer and autoimmune disorders.

Adaptive Biotechnologies Corporation issued $345 million in 0% convertible senior notes due 2031, generating approximately $334.5 million in net proceeds. The company used $156.9 million to repay the OrbiMed Purchase Agreement and $25.0 million to repurchase 1,451,800 shares of common stock. Adaptive Biotechnologies is a biotechnology company that develops immune system-based technologies for clinical and research use.

Adaptive Biotechnologies Corporation announced on June 15, 2026, its intention to offer $250 million in aggregate principal amount of convertible senior notes due 2031, with a 13-day option for initial purchasers to purchase an additional $37.5 million. The company also announced its intention to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses. Adaptive Biotechnologies is an immunology-focused biotechnology company.

Adaptive Biotechnologies Corporation held its annual meeting of shareholders on June 5, 2026, where shareholders voted to elect Robert Hershberg, PhD, MD and Katey Owen, PhD to the Board of Directors, approved the advisory compensation for 2025 named executive officers, and ratified Ernst & Young LLP as the independent registered public accounting firm for 2026. Adaptive Biotechnologies Corporation is an immunology-focused biotechnology company.